KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $168.8 million.

  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) rose 172.44% to $168.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.8 million, marking a year-over-year increase of 172.44%. This contributed to the annual value of $165.7 million for FY2024, which is 115.86% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $168.8 million, which was up 172.44% from $167.8 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $168.8 million for Q3 2025, and its period low was $160421.0 during Q2 2021.
  • In the last 5 years, Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $163.5 million in 2023 and averaged $121.2 million.
  • In the last 5 years, Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) plummeted by 9989.84% in 2021 and then soared by 10137171.49% in 2023.
  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $160493.0 in 2021, then surged by 100641.47% to $161.7 million in 2022, then grew by 1.32% to $163.8 million in 2023, then increased by 1.16% to $165.7 million in 2024, then grew by 1.88% to $168.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $168.8 million for Q3 2025, versus $167.8 million for Q2 2025 and $166.8 million for Q1 2025.